Celyad Oncology

Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)

Regulatory News:

Celyad Oncology (Euronext: CYAD) (the “Company” or “Celyad Oncology”) (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD), today announces the below information following the issuance, on 14 November 2023, of 14,903,846 new shares of Celyad Oncology SA (the “Company”) to an affiliate of Fortress Investment Group. As a result, the Company’s share capital has been increased to 88,378,224.25 EUR and is represented by 41,428,572 shares.

This information is published in accordance with Article 15 of the Belgian Law of 2 May 2007 on the disclosure of major participations in issuers whose shares are admitted to trading on a regulated market and regarding miscellaneous provisions.

Figures – Modified on 14 November 2023 following the capital Increase:

Total amount of share capital (EUR)	88,378,224.25
Total Number of shares with single voting rights	39,060,197
Total Number of shares with double voting rights	2,368,375
Total Number of Shares	41,428,572
Total of voting rights	43,796,947
Total number of attributed warrants	3,038,871
Total number of shares with voting rights that could be created following the exercise of the attributed warrants	3,038,871
Total number of diluted shares (Outstanding shares + Warrants)	44,467,443
Total number of diluted shares with voting rights	46,835,818

Contact person for regulated information (financial, transparency)

By law, any transparency declaration must be sent to our Company by email to the attention of Georges Rawadi, Chief Executive Officer (CEO): [e-mail].

Further questions about the content of this release can be sent to [e-mail].

About Celyad Oncology

Celyad Oncology is a cutting-edge biotechnology company dedicated to pioneering the discovery and advancement of revolutionary technologies for chimeric antigen receptor (CAR) T-cells. Its primary objective is to unlock the potential of its proprietary technology platforms and intellectual property, enabling to be at the forefront of developing next-generation CAR T-cell therapies. By fully leveraging its innovative technology platforms, Celyad Oncology aims to maximize the transformative impact of its candidate CAR T-cell therapies and redefine the future of CAR T-cell treatments. Celyad Oncology is based in Mont-Saint-Guibert, Belgium. For more information, please visit www.celyad.com.